Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

as grindeks, krustpils iela 53, riga, latvija - sitagliptinklorid hidrat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 100 mg sitagliptina u obliku sitagliptinklorid hidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

as grindeks, krustpils iela 53, riga, latvija - sitagliptinklorid hidrat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 25 mg sitagliptina u obliku sitagliptinklorid hidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

as grindeks, krustpils iela 53, riga, latvija - sitagliptinklorid hidrat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 50 mg sitagliptina u obliku sitagliptinklorid hidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

novatin limited, 230, second floor, eucharistic congress road, mosta, malta - sitagliptinklorid hidrat - filmom obložena tableta - urbroj: jedna tableta sadrži 100 mg sitagliptina u obliku sitagliptinklorid hidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - sitagliptinklorid hidrat - oralna otopina - urbroj: 1 ml oralne otopine sadrži sitagliptinklorid hidrat što odgovara 25 mg sitagliptina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - sitagliptinklorid hidrat - filmom obložena tableta - 100 mg - urbroj: jedna filmom obložena tableta sadrži sitagliptinklorid hidrat što odgovara 100 mg sitagliptina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - sitagliptinklorid hidrat - filmom obložena tableta - 25 mg - urbroj: jedna filmom obložena tableta sadrži sitagliptinklorid hidrat što odgovara 25 mg sitagliptina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - sitagliptinklorid hidrat - filmom obložena tableta - 50 mg - urbroj: jedna filmom obložena tableta sadrži sitagliptinklorid hidrat što odgovara 50 mg sitagliptina

Europska Unija - hrvatski - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Europska Unija - hrvatski - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.